1Zetter BR. Angioenesis and tumor metastasis [J]. Annu Rev Med,1998,49:407-424.
2Neufeld G, Cohen T, Gengrinovitch S, et al. Vascular endothelial growth factor(VEGF) and its receptors [J]. FASEB J, 1999,13 (1):9-22.
3Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factors[J]. Endocr Rev, 1997,18(1) :4-25.
4Takagi H, Otani A, Koyama S, et al. Selective induction of neuropilin-1 by vascular endothelial growth factor(VEGF) :amechanism contributing to VEGF-induced anglgenesis [J]. Proc Natl Acad Sci USA, 2002,99(1):383-388.
5Gondi CS, Lakka SS, Yanamandra N, et al. Expression of antisens uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and anglogenesis [J]. Oncogene,2003.22 (38):5967-5975.
6Dumont DJ,Jussila L,Taipale J, et al. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3 [J]. Science ( Washington DC ),1998,282(5390) :946-949.
7Partanen TA, Alitalo K, Miettinen H. Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor-3 in 185 Vascular tumors[J]. Cancer( Phila), 1999,86(11):2406-2412.
8Duff SE, Li C, Jeziorska M, et al. Vascular endothelial growth factors C and D and lymphangiogensis in gastrointestinal tract mailignancy[J]. Br J Cancer,2003,89(3) :426.
9Takahashi R,Tanaka S,Kitadai Y, et al. Expession of vascular endothelial growth factor and angiogenesis in gastrointestinal atromal tumor of the stomach[J]. Ontology, 2003,64(3):266.
2Martin Hu, Filipe MJ, Morris R, et al. p53 expression and prog nosis in gastric carcinoma [ J ]. Int J Cancer, 1993,50 (6): 859-862.
3Saito H, Tsujitani S, Kondo A, et al. Expression of vascular en dothelial growth factor correlates with hematogenous recurrence in gastric carcinoma [ J ]. Surgery, 1999,125 (2): 195-201
4Aas T, Borresen AL, Geisler S, et al. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients[J]. Nat Med,1996,2(5): 811-814.
5Maeda K, Ogawa M, Chung YS, et al. Overexpression of p53 associated with tumor angiogenesis, tumor cell proliferation, and prognosis in gastric carcinoma[ J]. Oncol Rep, 1997,4(3 ): 765- 768.
6Flejou JF, Fratio V, Muzeau F, et al. P53 abnormalities in ade nocarcinoma of the gastric cardia and antrum [ J ]. Mol Pathol, 1999,52(5 ), 263-268.
7Kakeji Y, Korenaga D, Tsujitani S, et al. Gastric cancer with p53 overexpression has high potential for metastasising to lymph nodes[J]. Br J Cancer,1993,67(3 ): 589-593.
4Folkman J.New perspectives in clinical oncology from angiogenesis research[J].Eur J Cancer,1996(14):2534-2539.
5Chen WS,Wei SJ,Lin JM,et al.Tumor invasiveness and livermetastasis of colon cancer cells correlated with cyclooxygenase 2(COX-2)expression and inhibited by a COX-2 selective inhibitor etodolac[J].Int J Cancer,2001(91):894-899.
6Levy GN.Prostaglandin H synthases,nonsteroidal anti-inflammatorydrugs and colon cancer[J].FASEB J,1997,11(4):234-247.
